Hepatotoxicity related to agomelatine and other new antidepressants: A case/noncase approach with information from the portuguese, French, Spanish, and Italian pharmacovigilance systems

Journal of Clinical Psychopharmacology

Volumn 34, Issue 3, 2014, Pages 327-330

  Montastruc, François ^a   Scotto, Stefania ^b   Vaz, Ines Ribeiro ^c,d   Guerra, Leonor Nogueira ^e   Escudero, Antonio ^f   Sáinz, María ^f   Falomir, Teresa ^g   Bagheri, Haleh ^a   Herdeiro, Maria Teresa ^c,d   Venegoni, Mauro ^b   Montastruc, Jean Louis ^a   Carvajal, Alfonso ^f  

^a TOULOUSE UNIVERSITY HOSPITAL   (France)

^b Centro Regionale di Farmacovigilanza   (Italy)

^c Faculty of Medicine   (United Kingdom)

^d Campus Universitário de Santiago   (Portugal)

^e INFARMED)   (Portugal)

^f UNIVERSITY OF VALLADOLID   (Spain)

^g Centro Regional de Farmacovigilancia de Las Illes Balears   (Spain)

Author keywords

antidepressants; case noncase approach; hepatotoxicity; pharmacovigilance databases

Indexed keywords

AGOMELATINE; AMFEBUTAMONE; AMINEPTINE; ANTIDEPRESSANT AGENT; CITALOPRAM; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; MIANSERIN; MIRTAZAPINE; NEFAZODONE; PAROXETINE; REBOXETINE; SERTRALINE; TIANEPTINE; TRAZODONE; VENLAFAXINE; ACETAMIDE DERIVATIVE;

ARTICLE; DEPRESSION; DRUG SURVEILLANCE PROGRAM; FRANCE; HUMAN; ITALY; LIVER TOXICITY; MAJOR CLINICAL STUDY; PORTUGAL; PRIORITY JOURNAL; RISK ASSESSMENT; SPAIN; TOXIC HEPATITIS; COMPARATIVE STUDY; DRUG-INDUCED LIVER INJURY; FACTUAL DATABASE; INCIDENCE;

ACETAMIDES; ADVERSE DRUG REACTION REPORTING SYSTEMS; ANTIDEPRESSIVE AGENTS; DATABASES, FACTUAL; DRUG-INDUCED LIVER INJURY; FRANCE; HUMANS; INCIDENCE; ITALY; PHARMACOVIGILANCE; PORTUGAL; SPAIN;

EID: 84900483011     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0000000000000094     Document Type: Article

References (28)

1. Temple RJ, Himmel MH. Safety of newly approved drugs: implications for prescribing. JAMA. 2002;287:2273-2275.
2. Watkins PB, Seeff LB. Drug-induced liver injury: summary of a single topic clinical research conference. Hepatology. 2006;43:618-631.
3. Navarro VJ, Senior JR. Drug-related hepatotoxicity. N Engl J Med. 2006;354:731-739.
4. Abboud G, Kaplowitz N. Drug-induced liver injury. Drug Saf. 2007;30:277-294.
5. Ostapowicz G, Fontana RJ, Schiødt FV, et al; U.S. Acute Liver Failure Study Group. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med. 2002;137:947-954.
6. Clinical Knowledge Summaries. Depression. National Institute for Helth and Care Excellence, last revised 2010. Available at: http://cks.nice.org.uk/ depression#!topicsummary. Accessed December 20, 2013.
7. Lucena MI, Carvajal A, Andrade RJ, et al. Antidepressant-induced hepatotoxicity. Expert Opin Drug Saf. 2003;2:249-262.
8. Choi S. Nefazodone (Serzone) withdrawn because of hepatotoxicity. CMAJ. 2003;169:1187.
9. Welcome withdrawal of amineptine in France. Prescrire Int. 1999;8:51.
10. Howland RH. A benefit-risk assessment of agomelatine in the treatment of major depression. Drug Saf. 2011;34:709-731.
11. Direct Healthcare Professional Communication on the risk of hepatotoxicity with agomelatine (valdoxan/thymanax). Available at: www.servier.com/sites/default/files/DHPC%20agomelatine.pdf. Accessed July 1, 2013.
12. Moore N, Kreft-Jais C, Haramburu F, et al. Reports of hypoglycaemia associated with the use of ACE inhibitors and other drugs: a case/non-case study in the French pharmacovigilance system database. Br J Clin Pharmacol. 1997;44:513-518.
13. Brown EG, Wood L, Wood S. The medical dictionary for regulatory activities (MedDRA). Drug Saf. 1999;20:109-117.
14. Evans SJ. Pharmacovigilance: a science or fielding emergencies? Stat Med. 2000;19:3199-3209.
15. Rothman KJ, Lanes S, Sacks ST. The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf. 2004;13:519-523.
16. Carvajal García-Pando A, García del Pozo J, Sánchez AS, et al. Hepatotoxicity associated with the new antidepressants. J Clin Psychiatry. 2002;63:135-137.
17. Montastruc JL, Sommet A, Bagheri H, et al. Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database. Br J Clin Pharmacol. 2011;72:905-908.
18. Hennessy S. Disproportionality analyses of spontaneous reports. Pharmacoepidemiol Drug Saf. 2004;13:503-504.
19. Otani K, Kaneko S, Tasaki H, et al. Hepatic injury caused by mianserin. BMJ. 1989;299:519.
20. Barbare JC, Biour M, Cadot T, et al. Hepatotoxicity of mianserin: a case with positive reintroduction. Gastroenterol Clin Biol. 1992;16:486-488.
21. Urbain D, Rodzynek JJ, Wettendorff P, et al. Hepatic toxicity of mianserin. Rev Med Brux. 1985;6:39-40.
22. Zarski JP, Aubert H, Rachail M. Toxicité hépatique des nouveaux anti-d épresseurs. A propos d'une observation. Gastroenterol Clin Biol. 1983;7:220-221.
23. Adverse Drug Reactions Advisory Committee. Mianserin: a possible cause of neutropenia and agranulocytosis. Med J Aust. 1980;2:673-674.
24. Riley RJ, Roberts P, Kitteringham NR, et al. Formation of cytotoxic metabolites from phenytoin, imipramine, desipramine, amitriptyline and mianserin by mouse and human hepatic microsomes. Biochem Pharmacol. 1990;39:1951-1958.
25. European Medicines Agency. CMHP assessment report for valdoxan. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Public- assessment-report/human/000915/WC500046226.pdf. Accessed July 1, 2013.
26. European Medicines Agency. CMHP assessment report for valdoxan. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/Summary-of-opinion- Initial-authorisation/human/000915/WC500059399.pdf. Accessed July 1, 2013.
27. Agomelatine (valdoxan/thymanax): risk of dose-related hepatotoxicity and liver failureVupdated warnings and monitoring guidance. Drug Safety Update [serial online]. October 2012, vol 6, issue 3: A1. Available at: http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON199558. Accessed July 1, 2013.
28. Muñoz Leon I, Sainz Gil M, Uribe F, et al. Hepatic function control in patients treated with agomelatine [in Spanish] Jornadas de Farmacovigilancia, Bilbao 2011, CP46, page 75. Available at: http://www.aemps.gob.es/eventosCongresos/2011/docs/libroResumenes-XI-jorBilbao. pdf. Accessed July 1, 2013.